our everyone has you, for year for us been And the on Orgenesis. transformative today. to thanks -- call This Thank David. on call joining
of field selling therapies. past the gene been the decade, to we've Over dedicated
growing obvious For made has in Personalized as field of healthcare that as well of it's this such us one industry, convergence and Healthcare Genetic as become the areas Engineering, the in Immuno-Oncology, for many fastest biotech. the areas
business. had we laying gene This into the divisions, which quality, services therapy business. our down point-of-care development of the cell manufacturing many to development and subsidiary, And incorporated our and was subcontracting though leading a clinical until our Masthercell business manufacturing companies. a centralized provided grown We another one foundation many of of and contract aspects, processing expertise have regulatory engineering developed areas in thus
and to this it pave understanding growing of as sell of we've proceeds matures of needs in the generating and on population. the $XXX marketing to of enable must serves it And realize economic viable we claiming’s on research sell of the for for to platform. order traditional the larger that much realized Masthercell in to for and it for answer capitalize this cannot support the stage goal for the $XXX strategic therapies to full way industry believe we the a was was with stage mind, gaining While in to our therapies. we shareholders based of could provide time it our to supplying a our our solution value products to field, who that decision needs expertise, millions pipeline development net gene developed companies, point-of-care roll-out approximately centralized order therapeutic while cell value and to solution provide subsidiary We approach Orgenesis. accelerate and million this and million, a to and cannot With Masthercell made Masthercell point-of-care the right partnerships the We the our clinical growing from the hospitals business. centres. benefit potentially maximize
that I of million the run that $XX $X think increased million end XXXX, annual of to -- understanding is years reflecting as to can we industry of farther illustration this growth revenue well our tremendous under the business. leadership. in-depth we build, We much point-of-care rate industry, just has to seen. CDMO the a our rate further this XX% the within run Based on also it's business has than as at of this expand rate five of important a CDMO note approximately a our compound potential from of believe strong business believe growth value the
industry, the work platform, without we costs and shareholders gene Masthercell, new therapies. resulted context, the of of to balance we the potential In cell provide and industry. shareholders. has building been across we've is us on believe will extremely hard capital cell tremendous which strategy standard now the and result high help sheet centralized To the meantime, unnecessarily As some for exceptional a gene at our unlock of value foundation the create execute therapy of diluting which in providing our the point-of-care full built the an historical sale point-of-care production, to
lower significant of have and of more inhibited to goal availability these per CAR-T necessary patients. our cost therapies is cell thousands therapies dramatically broadly available limited payers These -- uptake, costs, make is pay And patient. for is which therapies For can dollars for become by believe uptake to patients. significant hundreds available. crucial raise widely of these that will this We support a step to example,
costs, moment to therapies about and ideally to distribution. Let this logistics enhancing and decentralized point-of-care gene why platform, autologous I lowering me point-of-care of is our a cell take for patients providing model believe and talk suited streamlining by
the hospitals around built network. pillars; that the pillar therapy key developers first provides way technologies the in in described a past, our been the and streamlined a much the before. developers, we've our the more perspective of These therapies, aligned market. efficient is business path has of not patients therapy and As pillars From interests three the and done to
Our acquire or have adapt production goal to our is where ability in-license these pillars point-of-care to therapies to partner utilizing therapies the the second we technologies. our
close licence utilize these be to an the with able it the we third-parties. developed technologies, advanced partnered for Here are adapt production array are on-site, automation therapies Using of technologies supply. and we
R&D development we validation the technology all way than activity, stages and therapies our us to point-of-care this are development support our commercialization. centres. the of To-date and those have with the all continue of CRO partnerships in-licence combination integrated XX to through of clinical therapy to Our process and from developed to and allows more expand the processing pipeline
point-of-care forward scalability, and active providing are challenges key in look new efficacy, many These production to with discussions much a also centres manufacturing as control, updates believe in industry. off-cell more speed, We brief and which across We've technologies, the producibility, quality we address developments unfold. invested more. resources technologies adverse further
had platform, to efficient I'll such these of a cleanroom validation personnel, automated centres research of have These a simple OMPUL. GMP centralized integrate we as you basis procedures. of pillar slide illustrates requires and industry institutions these allow for effectively The but setup these a the advantages we pleased the period to compliant have of basis some OMPUL’s of harmonized hospital cost complex overcome them It power a us validation, the a involves OMPUL’s processes to that chance reduced but leading is production GMP Investor production to These size small and be has It's to the setup and processing. apparent footprint been with just few the our and therapies cell a to and our earning provide that our a systems, the we a OMPUL’s. more hospitals trained for up the around produce goal recent centres cleanroom to medical that, and lengthy in point-of-care of and facility strategy, hospitals therapies of cost research a you systems those related refer discuss And and for we Processing is the of therapies of costly. the difficult having a provide with What nightmare unveiling I institutes, I'm has are maintenance of lower and through or have therapies. a insufficient have platform. and response short cost building a tasks highly hospital. these systems major of point-of-care which time, to hadn't truly of extremely mobile talk production at the the overwhelming, and pleased name for call footprint, with setting on analysis as Units around units about will images facility explain the hospitals and them out a it in designed cleanrooms in haven't advanced supply also of to Our moment. these processing us, leading In even them from patients OMPUL’s on significant or I'd usually distribution challenges and to in number gene partnerships would to without to have regulatory building and other like and to report of automated cleanrooms the a therapies. manner. to But presentation hospitals historical costly especially of before these seen are deployed they latest utilized XX technologies, partnering in allowing at or they're process or the I risk maintaining the And announce for to the to is Mobile are rapidly logistical for small of and for be and a world. for direct In operation all and short website, am difficulty efficient will yet There doing for do OMPUL’s which expandable these time, our made is them at as implementing those network facilities, well line as to world. up high-grade with all centres global bottleneck unit many now Orgenesis supply countries third quality. they up single Labs the into and on-site timely these
an and look of in In agreements increase. local we've scalable design as partners autologous joint And capacity. a viral validate We've international centres format, processing modular XX cell service according expanding locations to Korea. of are committed hospital all venture established an in the and standardized important produce in we manner regulatory us addition, quality to with to and these hospitals. South consistent requirements. all of add the our the the needs along at factors locations. financially established and United systems. therapies therapies setup so of enable And can directly the we regional development network are point-of-care to forward to a States, both them We've with Israel Through capacity our point-of-care step additional expanding Belgium, and that We the gene we regional believe our and partners, these OMPUL’s capabilities
local partners have weeks coming months. the expect in requirements. agreements us more As and countries in to and point-of-care our I we with develop adapt many mentioned partners also XX now we to earlier, sign systems helping These and
pieces a a Are therapy fit if growing often to believe therapies breakdown therapy pillar business, public you this pillars. of world's investors a these cell on our each But we our is distribution. production and unrealized But are there’s more optimized in we pipeline we tremendous therapies for of component company, and see Are are business a look What each you the premier importantly, value believe bucket put do want by a companies. our our As each with of I we XX of developer? gene this? distributor? we manufacturer? these and cell in mean and a together, If the many par just first of with how
a we have of or recurrent importantly, Orgenesis our through unlock first is us As to the as OMPULIZING product the more value and product currently to Koligo. for working it. automated States working Kyslecel case acute full point commercial Koligo recognize a at our Kyslecel came already United with But the a which in pancreatitis. commercial potential. chronic acquisition production commercial Kyslecel, adapting to in for of say we platform point-of-care We're on-site, supplies U.S.,
our university venture gene agreement immuno-oncology Korea and Cure point-of-care of development and to yesterday, in formed immunotherapies. OMPUL just and global announced Therapeutics hospitals the on network, to a our we collaboration joint with gene we University therapies collaboration a a Through South Therapeutics therapy. Hospital cell and Inc Dong-a agreement we point-of-care for recent This developer basis. in commercialize this Cure these pipeline cell plan of with deploy our and agreements as of follows terms develop In
supply As all see therapeutic in across of we commercialize Orgenesis pipeline synergies harmony Japan, clearly can platform. and pillars and point-of-care a Korea South and develop, three we the
agreements and an in currently XX patent and of many an point-of-care we've space. pending underway that expect to have issued similar United two patents XX and applications around XX United announce enormous the international application. States the weeks. have patents, three for of States applications collaboration patent in patents, We platform, Supporting the XX or patent companies the rights we IPS We amassed PCT in own world pending pillars our exclusive coming
to that for building In defensible platform advantages addition other with moat compete make with point-of-care it than to mover players us [ph] advantage, our around collaborate rather first our a we're will industry us.
moment, revenue cell in revenues therapies of for a These Turning use. I'm systems pleased $X.X on XXXX to to setup for report million. time validation technology our financial to nearly and doubled related clinical for and
As we we revenue into future platform and the capacity good our point-of-care have growth. visibility our expand globally, allow
that in doubling revenue XXXX anticipate we just have. we than fact, In on more our contracts based existing
business of million providers our despite in cash, In we accelerate terms the the in having point-of-care ended capital. the our raise resources dramatically investment over of platform of to balance sheet, XXXX, significant with sale $XX year Masthercell to without point-of-care
funded we for a using in as plan well foreseeable the and very been will we future. we fact and in have We use opportunity future even biotech have in consider the which arises, place an
forward open may mentioned our our by But have. questions in number for the forward conferences happy on to wellness answer investors are are always quarterly the XXXX I calls attending to assets As state. significantly build earlier, look is investor holding We the undervalued upcoming conference we plan feel any and to going and we're goal of lines our company. a
shareholders, and more don't should to have the cell the am but therapy especially of a healthcare which extremely the of us be for driven of reason desire I the business, everything our only commitment our this and industry children sustainable the they all patients. advisors the be equally we lifesaving because the sustainable or for XXXX need appreciating afford encouraged a we transition not in that XXXX, progress therapies by that support our I'm I'm personal patients is have patient growth This grateful of There's cost dying outlook hundreds access can't and world confident of thousands to partners our cell global am in to and our around shareholders given created ever help It's truly up, our more period. not helped the meaningful very by genuine than and than industry. I by that during will I for no wrap appreciative will of adults did therapies. to to dollars. believe gene strong and gene also the in model our accomplish is shareholders, systems. achieve So our for -- global challenges more not pandemic. important personal employees, model
been capable many are very such continue for available government the the providing benefit receive to agencies technology fortunate eager systems us that used required support Technologies to health believe have countries. We adopting today care regulatory to are for crying of we And and expedite past innovative will providers are out from in collaborate support. approval we the us. and with in open are solutions solutions. The market to pathways can cost
be more our exciting I'll announced months to and note, Chief turn to in over and this So developments now sharing On weeks the Neil forward Financial Officer. to call we ahead. look the Reithinger,
